SeaStar Medical Holding (ICU) Price & Analysis

Compare

484 Followers

ICU Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.31 - $5.79

Previous CloseN/A

Volume52.61K

Average Volume (3M)3.11M

Market Cap

$25.57M

Enterprise Value-$1.48M

Total Cash (Recent Filing)$6.30M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-0.05

Next Earnings

Nov 12, 2025

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding27,914,597

10 Day Avg. Volume1,078,116

30 Day Avg. Volume3,105,544

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.06

Enterprise Value/Revenue-1.93

Enterprise Value/Gross Profit-2.00

Enterprise Value/Ebitda0.10

Forecast

1Y Price Target

$2.00

Price Target Upside117.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Commercial And Regulatory ProgressThe substantial potential of the SCD and early commercial and regulatory progress support a Buy rating for ICU.

Financial PerformanceSeaStar reported 2Q25 results with revenue of $338K, up 13.6% from the previous quarter, and a gross margin of 92.0%, which was above estimates.

Regulatory AchievementsThe FDA granted two new Breakthrough Device Designations for its Selective Cytopheretic Device (SCD) therapy.

Bears Say

Capital RequirementsICU will likely require significant capital to fund the trial, pursue regulatory approval, and support parallel development efforts across the SCD platform.

Financial ChallengesICU reported lower revenue and higher operational expenses than expected, indicating potential financial challenges.

SeaStar Medical Holding News

SeaStar Medical files to sell 10.92M shares of common stock for holders

17:06 EDT SeaStar Medical (ICU) files to sell 10.92M shares of common stock for holders Published first on...

24d ago

ICU

SeaStar Medical reaches new enrollment milestone in NEUTRALIZE-AKI trial

SeaStar Medical (ICU) announced that it has successfully reached enrollment of 125 patients in the NEUTRALIZE-AKI pivotal clinical...

26d ago

ICU

SeaStar Medical Appoints Interim CFO Amid Leadership Change

An update from SeaStar Medical Holding ( ($ICU) ) is now available. On August 13, 2025, SeaStar Medical...

13d ago

ICU

SeaStar Medical Reports Progress in Clinical Trials

Seastar Medical Holding Corporation ( ($ICU) ) has released its Q2 earnings. Here is a breakdown of the...

19d ago

ICU

SeaStar Medical Resumes Stock Offering with New Price

An update from SeaStar Medical Holding ( ($ICU) ) is now available. SeaStar Medical Holding Corporation, a company...

24d ago

ICU

SeaStar Medical Faces Nasdaq Listing Deficiency Notice

SeaStar Medical Holding ( ($ICU) ) just unveiled an update. On July 31, 2025, SeaStar Medical Holding Corporation...

26d ago

ICU

SeaStar Medical Announces Securities Purchase Agreement

SeaStar Medical Holding ( ($ICU) ) has provided an announcement. On July 31, 2025, SeaStar Medical Holding Corporation...

1M ago

ICU

SeaStar Medical announces $4.4M registered direct offering priced at-the-market

SeaStar Medical (ICU) announced it has entered into a definitive agreement for the issuance and sale of an...

1M ago

ICU

SeaStar Medical reports ‘positive’ results for QUELIMMUNE therapy in AKI

SeaStar Medical (ICU) announced “positive” preliminary results from the SAVE Surveillance Registry which is assessing the use of...

1M ago

ICU

SeaStar Medical Appoints New Board Chair Jennifer Baird

SeaStar Medical Holding ( ($ICU) ) has provided an update. SeaStar Medical Holding Corporation has announced the appointment...

2M ago

ICU

SeaStar Medical expands QUELIMMUNE Surveillence Registry

SeaStar Medical (ICU) has added a nationally-recognized, Texas-based children’s hospital to its growing customer base of QUELIMMUNE therapy...

2M ago

ICU

SeaStar Medical Announces $4M Securities Offering

SeaStar Medical Holding ( ($ICU) ) has provided an announcement. On July 10, 2025, SeaStar Medical Holdings Corporation...

2M ago

ICU

SeaStar Medical announces $4M registered direct offering

SeaStar Medical (ICU) Holding Corporation announced it has entered into a definitive agreement for the issuance and sale...

2M ago

ICU

SeaStar Medical expands Quelimmune adoption for pediatric patients

SeaStar Medical (ICU) announced that the Quelimmune therapy has been adopted for use by the nationally recognized Texas...

2M ago

ICU

ICU FAQ

What was SeaStar Medical Holding’s price range in the past 12 months?

SeaStar Medical Holding lowest stock price was $0.30 and its highest was $5.79 in the past 12 months.

What is SeaStar Medical Holding’s market cap?

SeaStar Medical Holding’s market cap is $25.57M.

When is SeaStar Medical Holding’s upcoming earnings report date?

SeaStar Medical Holding’s upcoming earnings report date is Nov 12, 2025 which is in 72 days.

How were SeaStar Medical Holding’s earnings last quarter?

SeaStar Medical Holding released its earnings results on Aug 13, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.25.

Is SeaStar Medical Holding overvalued?

According to Wall Street analysts SeaStar Medical Holding’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SeaStar Medical Holding pay dividends?

SeaStar Medical Holding does not currently pay dividends.

What is SeaStar Medical Holding’s EPS estimate?

SeaStar Medical Holding’s EPS estimate is -0.15.

How many shares outstanding does SeaStar Medical Holding have?

SeaStar Medical Holding has 27,914,597 shares outstanding.

What happened to SeaStar Medical Holding’s price movement after its last earnings report?

SeaStar Medical Holding reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went up 20.548%.

Which hedge fund is a major shareholder of SeaStar Medical Holding?

Currently, no hedge funds are holding shares in ICU

Company Description

SeaStar Medical Holding

SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

SeaStar Medical Holding (ICU) Earnings & Revenues

Historic Earnings Reports

ICU Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects significant progress in revenue and FDA approvals, alongside challenges in trial enrollment and operational delays. The company remains optimistic about future opportunities in both pediatric and adult markets.View all ICU earnings summaries

ICU Stock 12 Month Forecast

Average Price Target

$2.00

▲(117.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","11":"$11","17":"$17","23":"$23","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,5,11,17,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.66,0.7630769230769231,0.8661538461538462,0.9692307692307692,1.0723076923076924,1.1753846153846155,1.2784615384615385,1.3815384615384616,1.4846153846153847,1.5876923076923077,1.6907692307692308,1.7938461538461539,1.896923076923077,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.66,0.7630769230769231,0.8661538461538462,0.9692307692307692,1.0723076923076924,1.1753846153846155,1.2784615384615385,1.3815384615384616,1.4846153846153847,1.5876923076923077,1.6907692307692308,1.7938461538461539,1.896923076923077,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.66,0.7630769230769231,0.8661538461538462,0.9692307692307692,1.0723076923076924,1.1753846153846155,1.2784615384615385,1.3815384615384616,1.4846153846153847,1.5876923076923077,1.6907692307692308,1.7938461538461539,1.896923076923077,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.16,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.28,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >